- Details
- Rashid Sayyid and Zachary Klaassen discuss the 2024 NCCN prostate cancer guideline updates for systemic therapy in metastatic hormone-sensitive prostate cancer (mHSPC). They highlight the new stratification of treatment recommendations based on disease volume and timing of metastases. The discussion covers recent clinical trials supporting triplet therapy for high-volume synchronous disease, inclu...
|
- Details
- Alicia Morgans speaks with Bertrand Tombal about his presentation at EAU 2024, focusing on the European subset of the ARASENS trial. Professor Tombal discusses the importance of the data from this trial, which assessed the efficacy of adding darolutamide to standard treatment for metastatic hormone-naive prostate cancer. The trial confirmed that this combination significantly reduced mortality ris...
|
- Details
- Dingwei Ye introduces a conversation with Alicia Morgans, featuring insights from Professor Yao Zhu, Deputy Executive Director of Urology Surgery at Fudan University Shanghai Cancer Center, on the recent findings from the ARASENS study in the Chinese population. Professor Zhu shares that the study included 202 Chinese patients, about one-seventh of the total, revealing significant efficacy of daro...
|
- Details
- Alicia Morgans speaks with Yong YANG about prostate cancer in China, focusing on the ARASENS Phase 3 Clinical Trial. Professor YANG reveals that prostate cancer incidence in China is about 12 per 10,000, with a lower five-year survival rate than in the USA, largely due to late diagnoses. Approximately 60% of patients initially presented with metastasis. Treatment follows international guidelines a...
|
- Details
- Zach Klaassen hosts a discussion with Fred Saad about the ARASENS data and its transformative impact on prostate cancer treatment. This conversation primarily explores the correlation between a rapid, deep, and durable PSA response and excellent patient outcomes. Dr. Saad underlines the biological significance of a decline in PSA, noting how patients who achieve undetectable PSA levels significant...
|
- Details
- Alicia Morgans interviews Matthew Smith about the ARASENS Study and its implications for patients focusing on the study's secondary endpoints, including time to pain progression and skeletal-related events, which are crucial for understanding patient well-being. He emphasizes that the study included a diverse range of patients with varying disease characteristics, and the overall survival benefit...
|
- Details
- Alicia Morgans and Karim Fizazi discuss the ARASENS data and how it relates to whether patients with high-volume or low-volume metastatic castration-sensitive disease should be treated differently with systemic treatments. They explain that while historically, CHAARTED showed benefits in high-volume but not low-volume disease, STAMPEDE showed benefits for all patients regardless of volume. The rec...
|
- Details
- Matthew Smith joins Alicia Morgans to discuss the post hoc analysis of the ARASENS study reporting the impact of disease burden and risk on efficacy and safety outcomes. The positive findings from the ARASENS study showed a significant improvement in overall survival, and those results supported the regulatory approval of darolutamide as part of triplet therapy in men with metastatic hormone-sensi...
|
- Details
- In this UroToday Journal Club discussion, Zach Klaassen analyzes the Journal of Clinical Oncology publication, "Darolutamide Plus ADT and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial." The ARASENS trial, a multicenter, randomized, double-blind, placebo-controlled Phase III study across 23 countries, assesses the combi...
|
- Details
- Alicia Morgans and Karim Fizazi discuss quality of life and patient-relevant endpoints with darolutamide in the phase 3 ARASENS study and which patient populations benefit most from this data. Dr Fizazi also details the P6 platform. P6 is for all patients with metastatic castration-sensitive disease. There are different phase three trials called P6. Drs Morgans and Fizazi discuss the P6 vulnerable...
|
